TY - JOUR
T1 - Brucella exposure risk events in 10 clinical laboratories, New York City, USA, 2015 to 2017
AU - Ackelsberg, Joel
AU - Liddicoat, Anna
AU - Burke, Taryn
AU - Szymczak, Wendy A.
AU - Levi, Michael H.
AU - Ostrowsky, Belinda
AU - Hamula, Camille
AU - Patel, Gopi
AU - Kopetz, Virginia
AU - Saverimuttu, Jessie
AU - Sordillo, Emilia Mia
AU - D'Souza, David
AU - Mitchell, Elizabeth A.
AU - Lowe, William
AU - Khare, Reeti
AU - Tang, Yi Wei
AU - Bianchi, Anabella Lucca
AU - Egan, Christina
AU - Perry, Michael J.
AU - Hughes, Scott
AU - Rakeman, Jennifer L.
AU - Adams, Eleanor
AU - Kharod, Grishma A.
AU - Tiller, Rebekah
AU - Saile, Elke
AU - Lee, Stephen
AU - Gonzalez, Edimarlyn
AU - Hoppe, Brett
AU - Leviton, Ira M.
AU - Hacker, Susan
AU - Ni, Kuey Fen
AU - Orsini, Reina L.
AU - Jhaveri, Sangam
AU - Mazariegos, Irving
AU - Dingle, Tanis
AU - Koll, Brian
AU - Stoddard, Robyn A.
AU - Galloway, Renee
AU - Hoffmaster, Alex
AU - Fine, Annie
AU - Lee, Ellen
AU - Dentinger, Catherine
AU - Harrison, Emily
AU - Layton, Marcelle
N1 - Funding Information:
Yi-Wei Tang and Anabella Lucca Bianchi were supported in part by an NIH/NCI Cancer Center support grant (grant P30 CA008748). We report no additional sources of direct financial support. We acknowledge the following colleagues, who also contributed to this investigation: Alexandra Derevnuk and Angela Rendo (Mount Sinai Medical Center, New York, NY, USA), Maureen A. Bythrow (Northwell Health, Little Neck, NY, USA), Esther Babady, Arthur Brown (retired), Alexandra Franco Garcia, Susan Shuptar, and Ying Taur (Memorial Sloan Kettering Cancer Center, New York, NY, USA), and Paula Del Rosso, Mike Antwi, Marie Dorsinville, Ann Afordi, Renee Pouchet, Erlinda Amoroso (retired), Michele Middleton, Rajmohan Sunkara, and Yin Ling Leung (Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene, New York, NY, USA).
Funding Information:
Yi-Wei Tang and Anabella Lucca Bianchi were supported in part by an NIH/NCI Cancer Center support grant (grant P30 CA008748). We report no additional sources of direct financial support.
Publisher Copyright:
Copyright © 2020 American Society for Microbiology. All Rights Reserved.
PY - 2020
Y1 - 2020
N2 - From 2015 to 2017, 11 confirmed brucellosis cases were reported in New York City, leading to 10 Brucella exposure risk events (Brucella events) in 7 clinical laboratories (CLs). Most patients had traveled to countries where brucellosis is endemic and presented with histories and findings consistent with brucellosis. CLs were not notified that specimens might yield a hazardous organism, as the clinicians did not consider brucellosis until they were notified that bacteremia with Brucella was suspected. In 3 Brucella events, the CLs did not suspect that slow-growing, small Gram-negative bacteria might be harmful. Matrix-assisted laser desorption ionization- time of flight mass spectrometry (MALDI-TOF MS), which has a limited capacity to identify biological threat agents (BTAs), was used during 4 Brucella events, which accounted for 84% of exposures. In 3 of these incidents, initial staining of liquid media showed Gram-positive rods or cocci, including some cocci in chains, suggesting streptococci. Over 200 occupational exposures occurred when the unknown isolates were manipulated and/or tested on open benches, including by procedures that could generate infectious aerosols. During 3 Brucella events, the CLs examined and/or manipulated isolates in a biological safety cabinet (BSC); in each CL, the CL had previously isolated Brucella. Centers for Disease Control and Prevention recommendations to prevent laboratory-acquired brucellosis (LAB) were followed; no seroconversions or LAB cases occurred. Laboratory assessments were conducted after the Brucella events to identify facility-specific risks and mitigations. With increasing MALDI-TOF MS use, CLs are well-advised to adhere strictly to safe work practices, such as handling and manipulating all slow-growing organisms in BSCs and not using MALDI-TOF MS for identification until BTAs have been ruled out.
AB - From 2015 to 2017, 11 confirmed brucellosis cases were reported in New York City, leading to 10 Brucella exposure risk events (Brucella events) in 7 clinical laboratories (CLs). Most patients had traveled to countries where brucellosis is endemic and presented with histories and findings consistent with brucellosis. CLs were not notified that specimens might yield a hazardous organism, as the clinicians did not consider brucellosis until they were notified that bacteremia with Brucella was suspected. In 3 Brucella events, the CLs did not suspect that slow-growing, small Gram-negative bacteria might be harmful. Matrix-assisted laser desorption ionization- time of flight mass spectrometry (MALDI-TOF MS), which has a limited capacity to identify biological threat agents (BTAs), was used during 4 Brucella events, which accounted for 84% of exposures. In 3 of these incidents, initial staining of liquid media showed Gram-positive rods or cocci, including some cocci in chains, suggesting streptococci. Over 200 occupational exposures occurred when the unknown isolates were manipulated and/or tested on open benches, including by procedures that could generate infectious aerosols. During 3 Brucella events, the CLs examined and/or manipulated isolates in a biological safety cabinet (BSC); in each CL, the CL had previously isolated Brucella. Centers for Disease Control and Prevention recommendations to prevent laboratory-acquired brucellosis (LAB) were followed; no seroconversions or LAB cases occurred. Laboratory assessments were conducted after the Brucella events to identify facility-specific risks and mitigations. With increasing MALDI-TOF MS use, CLs are well-advised to adhere strictly to safe work practices, such as handling and manipulating all slow-growing organisms in BSCs and not using MALDI-TOF MS for identification until BTAs have been ruled out.
KW - Biosafety
KW - Brucellosis
KW - Laboratory-acquired infection
KW - Risk assessment
UR - http://www.scopus.com/inward/record.url?scp=85078687415&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078687415&partnerID=8YFLogxK
U2 - 10.1128/JCM.01096-19
DO - 10.1128/JCM.01096-19
M3 - Article
C2 - 31694974
AN - SCOPUS:85078687415
SN - 0095-1137
VL - 58
JO - Journal of Clinical Microbiology
JF - Journal of Clinical Microbiology
IS - 2
M1 - e01096-19
ER -